ABSTRACT
We report a case of malignant peritoneal mesothelioma with parasternal lymph node metastasis. The patient was a 34-year-old man who presented with a history of several years of abdominal pain and ascites of unknown origin. Exploratory laparoscopic biopsies yielded histological findings of malignancy, but a final diagnosis was not able to be made. A chest computed tomographic scan done the following year showed a parasternal nodule, and thoracoscopically obtained biopsied material was positive for calretinin. These findings led to a pathological diagnosis of metastasis to the parasternal lymph node from peritoneal mesothelioma.
Subject(s)
Lymphatic Metastasis , Mesothelioma/surgery , Peritoneal Neoplasms/surgery , Adult , Diagnosis, Differential , Humans , Laparoscopy , Male , Mesothelioma/diagnosis , Peritoneal Neoplasms/diagnosis , Thoracoscopy , Tomography, X-Ray ComputedABSTRACT
PURPOSE: The aim of this study was to evaluate the relationships among [18F]fluorodeoxyglucose ([18F]-FDG) uptake, Glut-1 and HK-II expressions, and grade of inflammation in resected lung lesions. MATERIALS AND METHODS: Sixty patients had undergone preoperative 18F-FDG-PET imaging and thoracotomy. For semiquantitative analysis of 18F-FDG uptake, partial volume effect corrected maximum standardized uptake values (pSUVs) were calculated. Immunohistochemical staining was performed in resected specimens using anti-Glut-1, anti-HK-II, and anti-proliferative cellular nuclear antigen (PCNA) antibodies, and immunoreactivities were scored as G-, H-, and P-indexes on a five-point scale (0: 0%; 1: 20%, 2: 40%; 3: 60%; 4: 80%, and 5: 100% percentages of strongly immunoreactive cells).Grade of inflammation was also evaluated. RESULTS: The malignant lesions had higher pSUV and higher G- and H- than nonmalignant lesions. pSUVs correlated with the G- (p < .001), H- (p < .01), and P-indexes (p < .01) in malignant lesions. In adenocarcinomas, cancers with lower differentiation showed higher expression of Glut-1 and HK-II than those with higher differentiation. A positive linear regression was observed between pSUVs and the grading of inflammation in nonmalignant lesions (p < .05). CONCLUSIONS: Our study indicates that 18F-FDG uptake in lung cancer correlates well with the Glut-1, HK-II, and PCNA expression. For nonmalignant lesions, the presence of a higher inflammatory process correlated with 18F-FDG uptake.
Subject(s)
Fluorodeoxyglucose F18/pharmacokinetics , Hexokinase/metabolism , Lung Neoplasms/diagnostic imaging , Monosaccharide Transport Proteins/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Radiopharmaceuticals/pharmacokinetics , Adenocarcinoma/metabolism , Adult , Aged , Cell Differentiation , Female , Glucose Transporter Type 1 , Humans , Image Processing, Computer-Assisted , Immunohistochemistry , Inflammation , Linear Models , Lung/metabolism , Lung Neoplasms/metabolism , Male , Middle Aged , Necrosis , Neoplasm Metastasis , Positron-Emission Tomography , Time Factors , Tuberculosis/metabolismABSTRACT
BACKGROUND: The nature of pulmonary nodules that appeared in patients who had received surgery for breast cancer, as well as the role of surgery for such pulmonary nodules, remains unclear. METHODS: A total of 52 consecutive patients who underwent surgery for pulmonary nodules between 1992 and 2001 after curative operation for breast cancer were reviewed. RESULTS: The pathologic diagnoses of pulmonary nodules were pulmonary metastases of breast cancer in 39 patients, primary lung cancer in 6, and other diagnoses in 7 (tuberculosis and hamartoma in 2 each; sclerosing hemangioma, organizing pneumonia, and paragohimiasis in 1 each). The incidence of multiple pulmonary nodules was significantly higher in metastatic breast cancer patients (64.1%), but 33.3% of primary lung cancer patients and 28.6% of other histology patients had multiple pulmonary nodules. The average disease-free interval from the initial mastectomy was significantly shorter in metastatic breast cancer patients (66.8 months), but disease-free intervals were longer than 5 years in 41.0% of metastatic breast cancer patients. The 5-year survival rate after pulmonary metastectomy of metastatic breast cancer patients was 30.8%, which was not better than those documented in metastatic breast cancer patients treated with modern chemotherapy. There was no significant difference in postmetastectomy survival according to the number or sites of pulmonary metastases or the disease-free interval. CONCLUSIONS: Pulmonary metastectomy may not be the primary therapeutic option in metastatic breast cancer patients, and patients should be treated principally with chemotherapy. As pulmonary nodules that appear in breast cancer patients are not always pulmonary metastases, the pathologic diagnosis should be confirmed, and surgery is an option for the pathologic confirmation.
Subject(s)
Breast Neoplasms/surgery , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Adult , Aged , Breast Neoplasms/pathology , Female , Humans , Lung Neoplasms/secondary , Middle Aged , Retrospective StudiesABSTRACT
Pleural involvement by a peripheral non-small cell lung cancer (NSCLC) is an important prognostic factor, but the accurate preoperative evaluation is sometimes difficult. We have already identified a feature on computed tomography (CT) that suggests a possible pleural involvement (pit-fall sign, i.e. multiple linear strands between the nodule and chest wall and/or inter-lobar fissure), and the clinical impact was assessed in the present study. A total of 103 consecutive peripheral NSCLC patients were prospectively examined, and the sensitivity, specificity, and accuracy of pit-fall sign in the diagnosis of pleural involvement were 83.3, 76.1, and 78.6%, respectively. The 5-year survival rate of pit-fall sign-positive patients was 46.5%, which was significantly lower than that of pit-fall sign-negative patients (68.9%; P = 0.044), and the prognostic significance was confirmed by a multivariate analysis. In conclusion, the pit-fall sign on preoperative CT suggests a possible pleural involvement correlated with a poor prognosis.
Subject(s)
Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Pleural Neoplasms/diagnostic imaging , Pleural Neoplasms/pathology , Aged , False Negative Reactions , Female , Humans , Male , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness , Prognosis , Prospective Studies , Sensitivity and Specificity , Survival Analysis , Tomography, X-Ray ComputedABSTRACT
Glomeruloid microvascular proliferation (GMP) is a focal proliferative budding of endothelial cells (ECs) resembling a renal glomerulus. Whereas some experimental and clinical studies have suggested recently that GMPs indicate an aggressive angiogenic phenotype, the incidence and clinical significance of GMPs remains unclear. Thus, we conducted a retrospective study on GMPs in a total of 236 patients with completely resected pathological (p-) stage I-IIIA NSCLC. ECs were highlighted with immunohistochemical staining using an anti-CD34 antibody, and GMPs were defined as focal glomerulus-like aggregates of closely associated and multilayer CD34-positive ECs. Expression of vascular endothelial growth factor, angiopoietin (Ang)-1, and Ang-2 was also examined immunohistochemically. GMPs were positive in 60 (25.4%) patients, and the incidence was not correlated with age, gender, histological type, or p-stage. The mean intratumoral microvessel densities for GMP-negative tumor and GMP-positive tumor were 178.2 and 184.1, respectively, showing that the incidence of GMPs was not correlated with intratumoral microvessel density (P = 0.676). There was no correlation between vascular endothelial growth factor expression and the incidence of GMPs, but GMPs were more frequently seen in Ang-1-positive tumor than in Ang-1-negative tumor. The 5-year survival rate of GMP-positive patients was 54.2%, which was significantly lower than that of GMP-negative patients (72.3%; P = 0.016). The 5-year survival rate of higher-MVD patients (71.5%) seemed to be lower than that of the lower-MVD patients (63.7%), but the difference did not reach a statistical significance (P = 0.137). A multivariate analysis confirmed that the presence of GMPs was a significant prognostic factor (P = 0.003), whereas MVD was not. In conclusion, GMPs indicate an aggressive angiogenic phenotype associated with a poor prognosis in NSCLC.
Subject(s)
Carcinoma, Non-Small-Cell Lung/blood supply , Lung Neoplasms/blood supply , Neovascularization, Pathologic/pathology , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Female , Humans , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Survival RateABSTRACT
We report here a case of solitary atypical adenomatous hyperplasia (AAH). A 17-year-old non-smoker man developed spontaneous pneumothorax, and computed tomogram scanning of his chest revealed a ground-glass opacity measuring 5 x 5 mm in the right lung with no change in its size for the next 7 months. To exclude the possibility of pulmonary neoplasia, he underwent partial pulmonary resection. The postoperative pathologic diagnosis was AAH. The present case is very exceptional for AAH because of the patient's young age and non-association with pulmonary carcinoma. The postoperative 23-month follow-up was uneventful.
Subject(s)
Lung/pathology , Pneumothorax/pathology , Adolescent , Cell Nucleus/pathology , Humans , Hyperplasia/pathology , Male , Pulmonary Alveoli/pathologyABSTRACT
Only a few clinical studies have documented a significant correlation between intratumoral microvessel density (IMVD), a measurement of angiogenesis, and apoptotic index (AI), an incidence of apoptosis, although many experimental studies have confirmed that insufficient angiogenesis induces accelerated apoptotic cell death. In the present study, therefore, to assess AI in correlation with IMVD in resected non-small cell lung cancer, a total of 236 patients with pathologic stage I to IIIa were reviewed. IMVDs were determined immunohistochemically with an antibody against a pan-endothelial marker, CD34 (CD34-IMVD), and an antibody against a proliferation-related endothelial marker, CD105 (CD105-IMVD). AI was defined as the number of tumor cells positive for the terminal deoxynucleotidyl tranferase-mediated dUTP-biotin nick end-labeling staining per 1000 tumor cells. When CD34 was used as a marker of angiogenesis, the mean AIs for the lower-IMVD and the higher-IMVD patients were 20.1 and 17.5, respectively, demonstrating no significant difference between the lower- and the higher-IMVD patients. In contrast, when CD105 was used, the mean AI for the lower-IMVD patients was significantly higher than that for the higher-IMVD patients (22.0 and 15.6, respectively; P=0.019). There was no significant correlation between proliferative activity and CD34-IMVD or CD105-IMVD. These results demonstrated that that decreased angiogenesis may induce enhanced apoptotic tumor-cell death without affecting cell proliferation.
Subject(s)
Antigens, CD34/analysis , Apoptosis , Biomarkers/analysis , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/pathology , Neovascularization, Pathologic , Vascular Cell Adhesion Molecule-1/analysis , Aged , Antigens, CD , Endoglin , Female , Humans , Immunohistochemistry , Male , Middle Aged , Receptors, Cell SurfaceABSTRACT
Angiopoietin (Ang)-1 and -2 have been recently identified as potent angiogenic factors which function in concert with vascular endothelial growth factor (VEGF), but no detailed clinical study on Ang expression has been reported. To assess the clinical significance of Ang expression in non-small cell lung cancer (NSCLC), a total of 236 patients with pathological stage-I-IIIA disease were retrospectively reviewed. Expression of Ang-1, Ang-2, or VEGF was examined immunohistochemically; intratumoral microvessel density (IMVD) was examined with immunohistochemical staining against CD34, a marker of pan-endothelial cells (CD34-IMVD), and that against CD105, a marker of proliferative endothelial cells (CD105-IMVD). Positive expression of Ang-1 and that of Ang-2 were seen in 101 (42.8%) and 40 patients (16.9%), respectively. There was no significant correlation between Ang-1 expression and CD34-IMVD or CD105-IMVD. In contrast, the average CD105-IMVD for Ang-2-positive tumor was significantly higher than that for Ang-2-negative tumor (56.7 versus 38.5; P = 0.032). More interestingly, such an angiogenic effect of Ang-2 was seen only when VEGF expression was high; when VEGF expression was high, the average CD105-IMVD for Ang-2-positive tumor was significantly higher than that for Ang-2-negative tumor (89.1 versus 63.6; P = 0.045); when VEGF expression was low, the average CD105-IMVD for Ang-2-positive tumor and that for Ang-2-negative tumor were almost the same (27.4 and 27.1, respectively). Moreover, positive expression of Ang-2, not Ang-1, was a significant factor to predict a poor postoperative survival (5-year survival rates for Ang-2-positive patients and -negative patients were 53.5 and 70.3%, respectively; P = 0.027), which was confirmed by a multivariate analysis. The influence of Ang-2 status on postoperative survival was enhanced when VEGF expression was high. That said, the 5-year survival of Ang-2-positive and VEGF-high patients was extremely low (41.4%) as compared with that for Ang-2-negative and VEGF-low patients (66.6%), as compared with that for Ang-2-positive and VEGF-low patients (63.6%), and as compared with that for Ang-2-negative and VEGF-low patients (71.8%). In conclusion, positive Ang-2 expression was significantly correlated with a poor prognosis, as well as with aggressive angiogenesis in resected NSCLC that was enhanced in the presence of high VEGF expression.
Subject(s)
Angiogenesis Inducing Agents/biosynthesis , Carcinoma, Non-Small-Cell Lung/metabolism , Lung Neoplasms/metabolism , Membrane Glycoproteins/biosynthesis , Aged , Angiopoietin-1 , Angiopoietin-2 , Carcinoma, Non-Small-Cell Lung/blood supply , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/surgery , Female , Humans , Lung Neoplasms/blood supply , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Male , Neovascularization, Pathologic/metabolism , Retrospective Studies , Treatment OutcomeABSTRACT
To clarify clinical characteristics and biological features of primary lung carcinoma arising from emphysematous bullae (EB), a total of 50 patients (49 males and one female) among all 1478 patients who underwent operation for primary lung carcinoma cases were reviewed; biological features were examined in 31 patients whose resected specimens were available for immunohistochemical staining (IHS). Thirty-one patients (62.0%) had pathologic stage I disease, and 30 cases (60.0%) had poorly differentiated tumor, demonstrating earlier pathologic stages and poorer cell differentiation of lung carcinoma with EB as compared with that without EB. The mean proliferative index (PI) for carcinoma with EB was 64.0%, which was significantly higher than that for carcinoma without EB (47.2%, P = 0.001); no significant difference in Apoptotic index (AI) was demonstrated. Aberrant p53 expression was less frequent in carcinoma with EB (29.0%) than in carcinoma without EB (47.9%, P = 0.043). Five-year survival rates for carcinoma with and that without EB were 50.3 and 46.9%, respectively, showing no significant difference. Multivariate analysis did not demonstrate that association of EB was a significant prognostic factor. In conclusion, although with the poorer cell differentiation and accelerated proliferative activity of lung carcinoma arising from EB, this does not have a significantly different prognosis than primary lung carcinoma not associated with bullae.